RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. [electronic resource]
Producer: 20121107Description: 3109-18 p. digitalISSN:- 1527-7755
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Core Binding Factor Alpha 2 Subunit -- genetics
- Cytogenetic Analysis
- DNA Mutational Analysis
- Disease Progression
- Disease-Free Survival
- Female
- Gene Expression Profiling -- methods
- Gene Expression Regulation, Neoplastic
- Genetic Predisposition to Disease
- Humans
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute -- drug therapy
- Logistic Models
- Male
- MicroRNAs -- metabolism
- Middle Aged
- Multivariate Analysis
- Mutation
- Nucleophosmin
- Oligonucleotide Array Sequence Analysis
- Phenotype
- Polymerase Chain Reaction
- Proportional Hazards Models
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
- United States
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.